Domov › Množni mielom › Tennessee › Nashville

Klinične študije za Množni mielom v Nashville, TN

32 študij za Množni mielom išče udeležence na lokacijah v Nashville in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Vključevanje udeležencevFaza 3

Research Site, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07391657

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Vključevanje udeležencevFaza 4

Sarah Cannon Research Institute, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05201781

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Vključevanje udeležencevFaza 3

SCRI Oncology Partners, Nashville
Vanderbilt University Medical Center, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07258511

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Vključevanje udeležencevFaza 3

Tennessee Oncology, PLLC, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07518186

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Vključevanje udeležencevFaza 1

Research Site, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07073547

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Vključevanje udeležencevFaza 3

Henry-Joyce Cancer Clinic, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05552222

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Vključevanje udeležencevFaza 1/2

Sarah Cannon Research Institute, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07116616

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Vključevanje udeležencevFaza 2

Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville

Starost 12 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT02693535

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Vključevanje udeležencevFaza 2/3

SCRI Oncology Partners /ID# 278353, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07095452

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Vključevanje udeležencevFaza 2

Tennessee Oncology, Nashville
Vanderbilt University Medical Center, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06297226

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Vključevanje udeležencevFaza 2

SCRI Oncology Partners, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07637578

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Vključevanje udeležencevFaza 1

Tennessee Oncology, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT06375044

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Vključevanje udeležencevFaza 1/2

Research Site, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 27. avg. 2026 · NCT07681596

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Vključevanje udeležencevFaza 2

GSK Investigational Site, Nashville

Starost 18 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT07227311

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Vključevanje udeležencevFaza 3

Ascension St. Thomas Hospital, Nashville
Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
in še 2

Starost 18 in več · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT06152575